SynOx Therapeutics raises EUR37m in Series A financing
SynOx Therapeutics Ltd (SynOx), a clinical stage biopharmaceutical company, has closed a EUR37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbion and Gimv. SynOx, a spin out of Celleron Therapeutics Ltd (Celleron), secured exclusive world-wide rights for the clinical development, manufacturing and commercialisation of emactuzumab